Drug intelligence / Profile preview

INM-176

Development stage
Phase 3
Lead developer
WhanIn Pharm
Modality
Small Molecules
Administration
Oral
01

Overview

INM-176 is a standardized ethanolic extract derived from the root of Angelica gigas Nakai, a plant traditionally used in Korean medicine. The extract contains bioactive compounds including decursin and decursinol, which function primarily as acetylcholinesterase (AChE) inhibitors. This mechanism increases brain levels of acetylcholine, a neurotransmitter essential for memory and cognition. INM-176 also exhibits neuroprotective properties through anti-inflammatory activities and protection against beta-amyloid peptide-induced neuronal damage. It has been investigated primarily for cognitive disorders including Alzheimer's disease and age-related memory impairment.

Other names
Alzheimer's therapeutic, Whanin PharmaceuticalsAnti-beta amyloid/AChE inhibitorAnti-beta amyloid/acetylcholinesterase inhibitor
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)AcetylcholinesteraseTNFA (Tumor necrosis factor alpha (soluble))NOS2 (Nitric Oxide Synthase 2)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on INM-176.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on INM-176.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call